MedTrace Logo

Chemotherapy and Radiotherapy for Osteolymphoma

NCT00141648 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2009-10-01

No results posted yet for this study

Summary

This trial is intended to determine the results obtained when standard treatment for Non Hodgkin's lymphoma is applied to the disease in a rare subtype which arises in bone. Patients in the study undergo a detailed assessment, then treatment with chemotherapy and radiotherapy, followed by close monitoring.

Conditions

  • Osteolymphoma

Interventions

DRUG

Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.

Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2

RADIATION

Radiotherapy

Total 45 Gy in 25 fractions

Sponsors & Collaborators

  • Australasian Leukaemia and Lymphoma Group

    collaborator OTHER

  • Australasian Radiation Oncology Lymphoma Group

    collaborator OTHER

  • Wesley Research Institute

    collaborator OTHER

  • Trans Tasman Radiation Oncology Group

    lead OTHER

Principal Investigators

  • David Christie, FRANZCR · East Coasr Cancer Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30
Primary Completion
2007-02-28
Completion
2008-02-29

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00141648 on ClinicalTrials.gov